research Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Inhibition of TNF-α-Induced Collagen Degradation and Oxidative Damage by Centipeda minima and Brevilin A in Human Dermal Fibroblasts
Centipeda minima and brevilin A protect skin cells from damage and aging.
research Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
research Hair Growth Stimulation Effect of Centipeda minima Extract: Identification of Active Compounds and Anagen-Activating Signaling Pathways
Centipeda minima extract helps hair grow by activating important growth signals and could be a promising hair loss treatment.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research Genetic Variation at the MC1R Locus and the Time since Loss of Human Body Hair
Humans lost body hair relatively recently in evolution.
research International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
Testosterone therapy can help postmenopausal women with low sexual desire if monitored carefully.
research Exploring caspase functions in mouse models
Caspases affect many cell functions and could help treat various diseases.
research Manifestaciones clínicas y complicaciones de la enfermedad por coronavirus 2019 (COVID-19): revisión de la literatura
COVID-19 symptoms range from mild to severe, with older adults at higher risk.
research Immunomodulatory roles of regulatory T cells in cutaneous wound healing: mechanisms and therapeutic opportunities
Regulatory T cells help heal skin wounds by reducing inflammation and promoting tissue repair.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research A Randomized Double-Blind Evaluation of a Novel Biotin and Silicon Ingredient Complex on the Hair and Skin of Healthy Women
LustrivaTM improves hair thickness and reduces facial wrinkles safely.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
research An Open-label Experience Trial to Evaluate the Effects of a Novel Supplement and Hair Serum Combination on Hair, Skin and Nails in Healthy Women
The LustrivaTM BH-002 supplement and hair serum improved women's hair, skin, and nail health and appearance.
research 0951 Breezula, a clinical stage topical anti-androgen, promotes dermal papilla inductivity and reduces IL-6 secretion in balding skin samples ex vivo
Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research LB1256 TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants
TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
research Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma
Lokivetmab reduced itching in a dog with skin lymphoma.
research A double-blind, placebo-controlled study with Kevis lotion
research A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements
VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.
research P62 Pre-clinical pharmacological and skin penetration profile of LDE255, a novel and specific Smoothened antagonist
LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Verilich hair serum in reducing hair shedding: A Case Report series
Verilich hair serum significantly reduces hair shedding and is safe to use.
research Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.